Dicloxacillin

CHEMBL893 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

470.3 g/mol

LogP

2.9

Phase

4

A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.

الوزن الجزيئي

470,3000 g/mol

LogP

2,90

TPSA

138,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Atopic Dermatitis

آلية العمل

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O

InChI

InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1

Molecular Formula

C19H17Cl2N3O5S

HBD / HBA

2 / 7

الروابط القابلة للدوران

4

الذرات الثقيلة

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Dicloxacillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL893. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 18381. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Dicloxacillin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C19H17Cl2N3O5S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.